NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- NB-4
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- ccle_lineage_sub_subtype
- M3
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+1.384
- MYC_TARGETS_V1+0.947
- E2F_TARGETS+0.728
- G2M_CHECKPOINT+0.530
- OXIDATIVE_PHOSPHORYLATION+0.401
- ALLOGRAFT_REJECTION+0.367
- DNA_REPAIR+0.329
- MTORC1_SIGNALING+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.227
- PI3K_AKT_MTOR_SIGNALING+0.155
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.587
- TGF_BETA_SIGNALING-0.524
- UV_RESPONSE_DN-0.483
- HEDGEHOG_SIGNALING-0.469
- PROTEIN_SECRETION-0.467
- MYOGENESIS-0.462
- APICAL_SURFACE-0.449
- ESTROGEN_RESPONSE_EARLY-0.358
- COAGULATION-0.329
- HYPOXIA-0.325
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SKNO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.949 |
| 2 | MOLM13_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.923 |
| 3 | SIGM5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.911 |
| 4 | TCGA-58-8387-01A-11R-2296-07 | — | cohortSQ2 | 0.892 |
| 5 | MV411_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.876 |
| 6 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.869 |
| 7 | U937_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.868 |
| 8 | TCGA-AR-A0TU-01A-31R-A109-07 | — | E | 0.856 |
| 9 | 98e3beb5-bff2-4c4e-b492-c4ed7dda9d9c | — | — | 0.854 |
| 10 | 20030039.TNBC | — | E | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 1.384 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.947 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.728 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.401 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.367 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.329 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.227 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.155 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.109 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.098 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.094 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.046 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.042 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.032 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.029 | Idelalisib | — uncovered |